Skip to Main Content (Press Enter)

Logo UNINSUBRIA
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNINSUBRIA

|

UNI-FIND

uninsubria.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Insegnamenti

SCV0725 - NOVEL ANTICANCER THERAPIES

insegnamento
ID:
SCV0725
Durata (ore):
48
CFU:
6
SSD:
FARMACOLOGIA
Anno:
2024
  • Dati Generali
  • Syllabus
  • Corsi
  • Persone

Dati Generali

Periodo di attività

Secondo Semestre (24/02/2025 - 20/06/2025)

Syllabus

Obiettivi Formativi

The course is designed to provide an updated overview of the molecular and cellular mechanism(s) of action (and resistance) of novel approaches to the clinical management of cancer, that are increasingly associated with, and in some case have replaced, conventional cytotoxic chemotherapy.
Students will become familiar with endocrine, antiangiogenic and immunotherapeutic agents, as well as the very recent strategies based on engineering of autologous or allogeneic cells; they will learn about the experimental models and tools that lead to the discovery of new strategies and drug targets.

Prerequisiti

To fully understand the topics addressed in the course, students should have basic notions of cellular biology and pathology and of general pharmacology

Metodi didattici

The teaching activity consists of frontal lectures in the classroom with the support of power point slide presentations and scientific articles. Lecture slides will be made available to all students on the e-learning platform after the end of each lesson.
Lectures and the accompanying visual materials are the major source of information for the student. Thus, consistent attendance is recommended.
Highly recommended reading:
Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1):31-46. doi:10.1158/2159-8290.CD-21-1059
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. doi:10.1016/j.immuni.2013.07.012

Verifica Apprendimento

The learning outcomes will be assessed by a final oral exam consisting of three questions. The first will aim at discussing a general pharmacology content (inspired to the title of a lesson), to evaluate the student’s ability to organize the presentation of a general topic as well as the acquired knowledge. The second question will be on a specific druggable molecule/molecular pathway. The third question will regard immunotherapy approaches. The results of the exam will be out of thirty. The exam will be passed with a score of 18/30. Full marks (greater than 28/30), and possibly honors, will be awarded to students demonstrating to have acquired the knowledge on the subjects of the course and able to present the concepts clearly and with appropriate terminology.

Contenuti

The course will consist of lectures organized in two parts focused on: 1) an extensive introduction to anticancer therapies with a large overview encompassing the key aspects of antitumor pharmacology in a historical perspective that provides the ground to present the novel therapeutic strategies, 2) molecularly targeted agents and immunotherapy as well as new aspects of tumor biology that are expected to inform future therapies

Lingua Insegnamento

INGLESE

Altre informazioni

The teacher will receive the students upon appointment scheduled by e-mail.

Corsi

Corsi

BIOMEDICAL SCIENCES 
Laurea Magistrale
2 anni
No Results Found

Persone

Persone

PEREGO PAOLA MARIA CHIARA
Docenti
No Results Found
  • Accessibilità
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 25.5.5.0